Research summary, narrative review, 2018

Lead Aprons and Thyroid Shields in Interventional Pain Management

Cheon BK, Kim CL, Kim KR, Kang MH, Lim JA, Woo NS, et al.. The Korean journal of pain. 2018

Read the original paper

In plain language

This review of pain-management fluoroscopy finds that well-fitting lead aprons and tight thyroid shields keep physician doses within limits in reported studies, but eyewear use and radiation safety training among Korean pain physicians are low.

At a glance

Type of study
Narrative review
Who was studied
Other physicians
Where
South Korea
Summary based on
the full text

What it found

  • Across reviewed studies, pain physicians' radiation exposure was within safety limits when lead aprons and thyroid shields were used, though stochastic risk remains.

  • A 0.5 mm apron attenuates about 90% or more of scatter; lead glasses reduce more than 95%.

    Key figures: ≥90%; >95%

  • Thyroid shields reduce effective dose substantially, and wearing them tightly lowers thyroid dose versus loose wear.

    Key figures: 2.5-fold effective dose reduction; ~50% total exposure

  • In Korean surveys, lead glasses were worn far less often than aprons or thyroid shields.

    Key figures: aprons 93-100%, thyroid shields 81-100%, glasses 38-40%

  • Most Korean pain physicians had never received radiation safety education, and education did not change practice.

    Key figures: 61%

Limits to keep in mind

Narrative review with a non-systematic PubMed search of the last 10 years; relies on few, small dosimetry studies in pain management and does not appraise study quality.

How this summary was made

ORSIF prepared this summary with AI assistance from the full text of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.